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Purpose: Several mass spectrometry-based methods for antimicrobial sensitivity testing 
have been described in recent years. They offer an alternative to commercially available 
testing systems which were considered to have disadvantages in terms of cost- and time- 
efficiency. The aim of this study was to develop an LC-MS/MS-based antibiotic hydrolysis 
assay for evaluating antimicrobial resistance (AMR) of Gram-negative bacteria.
Materials and Methods: Four species of Gram-negative bacilli (Klebsiella pneumoniae, 
Escherichia coli, Providencia stuartii and Acinetobacter baumannii) were tested against six 
antibiotics from three different classes: ampicillin, meropenem, imipenem, ceftazidime, 
ceftriaxone and cefepime. Bacterial suspensions from each species were incubated with 
a mixture of the six antibiotics. Any remaining antibiotic following incubation was measured 
using LC-MS/MS. The results were interpreted using measurements obtained for an E. coli 
strain sensitive to all antibiotics and expressed as percentage of hydrolyzed antibiotic. These 
were subsequently compared to commercially-available system for the bacteria identification 
and susceptibility testing.
Results: Overall, LC-MS/MS assay and commercial antimicrobial susceptibility platform 
results showed good agreement in terms of an organism being resistant/sensitive to an 
antibiotic. The time required to complete the LC-MS/MS-based hydrolysis test was under 
5 h, significantly shorter that commercially available susceptibility testing platforms.
Conclusion: By using a sensitive strain for results interpretation and simultaneous use of 
multiple antibiotics, the proposed protocol offers improved robustness and multiplexing over 
previously described methods for antibiotic sensitivity testing. Nevertheless, further research 
is needed before routine assimilation of the method, especially for strains with intermediate 
resistance.
Keywords: antimicrobial, resistance, β-lactamases, LC-MS/MS, Gram-negative, mass 
spectrometry
Introduction
Antimicrobial resistance (AMR) is an increasing health concern. It is regarded as a global 
threat which will have a severe negative impact on health management. The increased β- 
lactam resistance in Gram-negative pathogens makes the optimizing of antibiotic thera-
pies against carbapenemases or extended-spectrum β-lactamases (ESBL) producing 
bacteria extremely challenging.1–3 Systemic infections due to these β-lactamase produ-
cing strains are associated with higher morbidity and mortality.4
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A fast and accurate method is required for detection of 
carbapenemases or ESBL producing organisms is required 
in medical laboratories. Commercial automated systems 
that can be used for both microorganism identification 
and antimicrobial susceptibility testing (AST) are com-
monly used nowadays.5,6 Depending on the organism, 
the results are obtained between 3 and 24 h.6–8
To reduce the turnaround time for AST, and to clarify 
the resistance mechanism, several mass spectrometry- 
based methods have been developed. The success of 
matrix-assisted laser desorption time-of-flight mass spec-
trometry (MALDI-TOF MS) for microbial identification 
has drawn interest in using the technique for AST. 
Different approaches have been reported using this tech-
nique, these include: comparing differences in protein 
expression,9 detection of β-lactamase itself,10 and antibio-
tic hydrolysis assay.11,12 Of these, the β-lactamase hydro-
lysis assay has been commercialized.13 The principle of 
the method is based on analyzing the mass spectra of β- 
lactam antibiotics before and following incubation with 
a bacterial culture.
Although it has been shown that MALDI-TOF can be 
used for detection of β-lactamase activity, the assay is 
susceptible to interferences that can arise from matrix ions 
and it cannot be used effectively for quantitative analysis.14 
As precise quantitation of unhydrolyzed antibiotic will 
reflect the level of enzyme activity more accurately, 
a better suited method is needed. Liquid chromatography 
coupled with tandem mass spectrometry (LC-MS/MS) is 
ideally suited for quantitative analysis of small molecules 
from complex matrices, thus it can be used to accurately 
quantitate the level of antibiotic remaining after 
hydrolysis.15–19
In this study, we aimed to determine AMR activity of 
β-lactamase producing Gram-negative bacteria using 
a LC-MS/MS-based antibiotic hydrolysis assay, and to 
compare the LC-MS/MS results to a widely used commer-
cial antimicrobial susceptibility platform.
Materials and Methods
Standards and Reagents
Meropenem, imipenem, ceftazidime, ceftriaxone and 
ampicillin (all of analytical standards or of certified refer-
ence standards) were purchased from Sigma-Aldrich 
(St. Louis, MO, USA) and cefepime hydrochloride mono-
hydrate powder was acquired from Alfa Aesar (Ward Hill, 
MA, USA).
Acetonitrile (HPLC-grade) was purchased from 
AppliChem GmbH (Darmstadt, Germany) while formic 
acid (HPLC-grade), di-sodium hydrogen phosphate, sodium 
dihydrogen phosphate dihydrate and zinc chloride were 
obtained from Merck (Darmstadt, Germany). HPLC-grade 
water was purchased from VWR International (Radnor, 
Pennsylvania, USA) while Columbia 5% sheep blood agar 
was from Sanimed (Bucharest, Romania).
Bacterial Strains
The bacterial strains used in this study were obtained from 
the routine clinical activity of the “Pius Brînzeu” Emergency 
Clinical County Hospital, Timișoara (PBECCHT) Clinical 
Laboratory. The reference strains were purchased from 
Thermo Scientific (Lenexa, Kansas, USA). Identification of 
all clinical isolates was performed using a commercial anti-
microbial susceptibility platform (Vitek® 2 System, bio- 
Mérieux, Marcy l’Etoile, France).
AST was tested according to the Clinical Laboratory 
and Standards Institute (CLSI) criteria, which is by deter-
mining the minimum inhibitory concentration (MIC) using 
the commercial antimicrobial susceptibility platform.20 
Phenotypic confirmation of ESBL production was done 
using the synergy test between extended-spectrum cepha-
losporins and clavulanic acid and the double disk synergy 
test with cefotaxime, ceftazidime and cefepime with and 
without clavulanic acid.21 Carbapenemase production was 
demonstrated by the modified Hodge test and by combined 
disk diffusion method (KPC, MBL and OXA-48 Confirm 
kit, Rosco Diagnostica, Denmark).12,22 Table 1 gives 
a description of the strains used.
Hydrolysis Test
The bacterial strains were grown on Columbia 5% sheep 
blood agar for 24 h at 37°C. Suspensions of bacteria culture 
were prepared in 100 mM phosphate buffer pH 7, containing 
10 µg/mL ZnCl2. The turbidity was adjusted equivalent to 
McFarland 4 using a densitometer (Densimat, bioMérieux, 
Italy). In a 1.5 mL centrifuge tube, 100 µL of bacteria 
suspension was mixed with 10 µL of antibiotic reaction 
mix (containing 5 mg/mL ampicillin and 0.5 mg/mL cef-
triaxone, ceftazidime, cefepime, meropenem and imipenem) 
and then incubated for 2 h at 37°C. A negative control was 
also prepared by incubating, under the same conditions, 
100 µL of phosphate buffer with 10 µL of the mixture of 
antibiotics. An aliquot (200 µL) of ice-cold acetonitrile was 
subsequently added and the samples were centrifuged at 
10,000 g for 5 min. The supernatant (100 µL) was mixed 
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with 300 µL HPLC-grade water and an aliquot was analyzed 
using LC-MS/MS.
LC-MS/MS Analysis
The LC-MS/MS system used comprised of a Shimadzu 
Nexera X2 UHPLC hyphenated to a LCMS-8045 triple 
quadrupole mass spectrometer (Shimadzu Corporation, 
Kyoto, Japan). The chromatographic separation was 
achieved using an Onyx Monolithic C18 column (100 
x 3 mm) from Phenomenex (Torrance, CA, USA) equipped 
with an Onyx Monolithic C18 guard cartridge (5 x 3 mm) 
also from Phenomenex. A binary gradient consisting of “A” 
- 0.1% formic acid in water and “B” - 0.1% formic acid in 
acetonitrile was used. The elution profile started at 15% 
B then increased to 75% over 1 min, it was maintained at 
this level for 2 min and then returned to 15% B over 30 sec. 
The column was equilibrated at this level of B for 6.5 min 
between injections. The flow rate was set to 0.3 mL/min. 
Column oven and autosampler temperature was set to 
40 and 5°C respectively. An injection volume of 5 µL 
used was. The mass spectrometer was equipped with an 
electrospray ionization (ESI) source and operated in 
a positive mode. The MRM transitions (Table 2) were 
optimized by direct infusion of the standards at 
a concentration of 10 µg/mL.
Calibration standards were prepared in the concentra-
tion range 0.625 to 10 µg/mL for ampicillin; and 0.0625 to 
1 µg/mL for meropenem, imipenem, ceftazidime, ceftriax-
one and cefepime.
The MS data were acquired and processed using 
LabSolution® software (v 5.91/2017, Shimadzu Corporation, 
Kyoto, Japan). Integration of HPLC-peaks was performed 
using the i-PeakFinder algorithm for all compounds. Spectra 
were smoothed (standard method - 5 counts and width - 5 sec) 
and correction was applied to the baseline (1-degree baseline 
following degree). Peak identification was performed using 
absolute retention time (RT). Reference ion ratio allowance 
was set to 30%. Quantification was performed using an exter-
nal calibration with linear fit and not forced though zero.
Test Validation
The LC-MS/MS validation procedure included linearity, 
limit of detection (LOD), limit of quantification (LOQ), 
accuracy, precision. The LOD and LOQ were automati-
cally calculated using the instrument software. The lowest 
concentration detectable with a signal-to-noise (S/N) ratio 
of ≥ 3:1 was used to establish the LOD, whilst the lowest 
concentration measurable with a signal-to-noise (S/N) 
ratio of ≥ 10:1 was used to establish the LOQ.
Accuracy was determined by carrying out ten repeated 
injections of each calibration standards. Precision was 
assessed by carrying out five repeated injection of one 
sample. Repeatability of the hydrolysis test was assessed 
by repeating the incubation five times using E. coli ATCC 
25,922 and K. pneumoniae ATCC BAA-1705 strains and 
Table 1 Strain Description with Phenotypic Confirmation of 
ESBL and Carbapenemase Production


















Klebsiella pneumoniae (1) - +/KPC
Klebsiella pneumoniae (2) + +/KPC
Providencia stuartii - +/OXA 48
Acinetobacter baumannii - +/OXA 48
Escherichia coli (1) + NA
Escherichia coli (2) + NA
Escherichia coli (3) + NA
Abbreviations: ESBL, extended spectrum β-lactamase; MHT, modified Hodge test; 
CDDM, combined disk diffusion method; ATCC, American Type Culture 
Collection; AMP, ampicillin; CAZ, ceftazidime; CRO, ceftriaxone; FEP, cefepime; 
IMI, imipenem; MEM, meropenem; MHT, modified Hodge test; NA, not applicable.














Abbreviations: MRM, multiple reaction monitoring; m/z, mass to charge.
Infection and Drug Resistance 2020:13                                                                                     submit your manuscript | www.dovepress.com                                                                                                                                                                                                                       
DovePress                                                                                                                       
4023



































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
determining the antibiotic concentration from each test 
tube. The relative standard deviation (RSD%) of peak 
area was calculated for each antibiotic. This was used to 
estimate the standard uncertainty of the measurement. 
All values were calculated using LabSolution software 
(v 5.91/2017, Shimadzu, Corporation, Kyoto, Japan).
Data Interpretation
The sensitive E. coli ATCC 25,922 strain was used as 
negative control, the antibiotic concentrations obtained 
after incubation with this strain were considered as refer-
ence. The level of antibiotic detected in samples where 
bacteria were incubated with mixture of antibiotics was 
calculated relative to the negative control and expressed as 
percentage of hydrolyzed antibiotic.
The RSD% values from test validation was used to 
establish the limit where hydrolysis is considered present. 
For this purpose, the precision test results were used to 
establish the range of uncertainty out of which the hydro-
lysis was considered to be present. For example, for an 
antibiotic in which the accuracy of the test result was 10%, 
β-lactamase catalyzed hydrolysis was considered present if 
less than 90% could be detected. If more than 90% of the 
antibiotic could be detected, we deemed the organism not 
to have any β-lactamase activity.
The specificity of the LC-MS/MS antibiotic hydrolysis 
assay were evaluated using IBM-SPSS version 25 (IBM, 
Armonk, New York, USA) using Crosstabs. The MIC test 
results were used as reference.
Ethics Statement
This study was approved by the Ethics Committee of the 
“Pius Branzeu” Timisoara Emergency Clinical County 
Hospital (ref. no. 175/18 Oct. 2019).
Results
A multiple reaction monitoring (MRM) method was devel-
oped for all antibiotics. Two transitions per compound were 
used: one was used for quantification ion and the other for 
confirmation. All antibiotics eluted within 3 min and chro-
matograms showed good peak shapes. The MRM chroma-
tograms for standards solution (5 µg/mL for ampicillin, and 
0.5 µg/mL for imipenem, meropenem, ceftriaxone, cefe-
pime and ceftazidime) are shown in Figure 1. LODs (S/N 
≥ 3:1) were situated in 0.05–2.38 ng/mL interval while 
LOQs (S/N ≥ 3:1) were in 0.015–7.2 ng/mL interval. The 
five-point calibration curves showed a very good concen-
tration/response correlation with R-squared value for all 
analytes being greater than 0.98. The retention time, 
LODs, LOQs, and results for accuracy and precision tests 
are presented in Table 3.
Using precision test (RSD%), the presence of β- 
lactamase activity was deemed present when more than 
10% of antibiotic was hydrolyzed for ampicillin, imipe-
nem, meropenem and cefepime; and more than 15% for 
ceftriaxone and ceftazidime. The results from the LC-MS 
/MS antibiotic hydrolysis assay compared with the mini-
mum inhibitory concentration test for all organisms tested 
are shown in Table 4.
A comparison between hydrolysis levels of each 
antibiotic for three representative strains (ESBL- and carba-
penemase-producing K. pneumoniae, carbapenemase- 
producing A. baumannii and ESBL-producing E. coli), are 
displayed in form of bar chart in Figure 2.
The LC-MS/MS results showed good agreement with 
MIC test, except for one K. pneumoniae strain for which 
the LC-MS/MS result was sensitive to cefepime compared 
to MIC test where the result was sensitive dose dependent 
(SDD), and one E. coli strain for which the LC-MS/MS 
result was sensitive to ceftazidime compared to MIC test 
where the result was intermediate. The assay specificity 
was 100% for ampicillin, meropenem, imipenem and cef-
triaxone; and 87.5% for cefepime and ceftazidime.
Discussion
The evidence of a high risk of increased mortality among 
patients with systemic infections, in the event of a failure 
to control the pathogen during the first 24–48h23–25 was an 
important reason for conducting this study. For this pur-
pose, a fast LC-MS/MS assay was developed and applied 
to detect β-lactamases activity in Escherichia coli, 
Klebsiella pneumoniae, Providencia stuartii and 
Acinetobacter baumannii clinical isolates based on their 
ability to hydrolyze β-lactams in solution.
Although detection of resistance to carbapenems and 
cephalosporins in Gram-negative bacilli using LC-MS 
/MS was previously described,16–19 the present study 
brings a new approach for results interpretation and 
a simultaneous detection of hydrolysis of six antibiotics 
from three different classes of β-lactams. Selection of 
antibiotics and bacterial strains was based on the findings 
from previous studies in which numerous strains of 
Enterobacterales and Acinetobacter baumannii with 
acquired resistance to broad-spectrum cephalosporins 
and carbapenems were reported.1,2 We also used two 
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strains with intermediate resistance to highlight the lim-
itation of the assay.
During method validation stage, our key aim was to 
assess the precision of the assay. This was considered 
important mainly for avoiding false positive results. For 
this purpose and to ensure that the results were 
reproducible, we repeated the hydrolysis experiment and 
subsequent LC-MS/MS analysis on different days. The 
range of uncertainty established in the validation study 
was used for result interpretation to help decide if hydro-
lysis is present. The current study proposed a protocol 
which implies the use of a reference strain sensitive to all 
Figure 1 MRM chromatograms of mixture of ampicillin (5 µg/mL), imipenem (0.5 µg/mL), meropenem (0.5 µg/mL), ceftriaxone (0.5 µg/mL), cefepime (0.5 µg/mL), and 
ceftazidime (0.5 µg/mL) dissolved in phosphate buffer.
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antibiotics used. Furthermore, the degree of β-lactamase 
activity for an organism was calculated relative to this 
negative control, thus accounting for auto hydrolysis and 
matrix interferences. The interpretation of results can be 
easily automated by using a formula that uses test sample 
and control measurement together with range of uncer-
tainty (%), thus eliminating any subjective interpretation.
The concentration of antibiotics used for determining 
β-lactamase activity that had been established in previous 
work15 was used with minor changes. A less concentrated 
Table 3 Accuracy, Precision, Retention Time, LODs and LOQs for Each Antibiotic
Compound Accuracy – RSD (%) * Precision – RSD (%) ** RT Min RT RSD% LOD ng/mL LOQ ng/mL
Ampicillin 1.6 4.4 2.6 0.6 0.3 1
Imipenem 0.3 6.2 2 0.1 0.1 0.2
Meropenem 3.9 5.4 2.3 0.2 0.1 0.2
Ceftriaxone 2 11.9 2.7 0.2 2.4 7.2
Cefepime 4.2 6.9 2.1 0.4 0.2 0.6
Ceftazidime 5.7 14.6 2.4 0.1 0.2 0.5
Notes: *Determined by ten repeated injections of each calibration standards, **Assessed by repeating the hydrolysis test five times using E coli ATCC 2592. 
Abbreviations: RT, retention time; RSD, relative standard deviation; LOD, limit of detection; LOQ, limit of quantification.
Table 4 LC-MS/MS Antibiotic Hydrolysis Assay Compared with the Minimum Inhibitory Concentration Test. For Antibiotic Hydrolysis 
Assay, The Strains Were Incubated for 2 h at 37°C with a Mixture of Antibiotics
Strains Test AMP IMI MEM CRO FEP CAZ
K. pneumoniae ATCC BAA-1705 LC-MS/MS results* 5.7/R 3.3/R 1.4/R 2.5/R 3.9/R 27.5/R
MIC results** ˃128/R 8/R ˃ 16/R 64/R 16/R ≥ 64/R
K. pneumoniae ATCC 700,603 LC-MS/MS results* 5.4/R 90.4/S 92.2/S 35.3/R 98.6/S 39.5/R
MIC results** ˃ 128/R 0.25/S 0.25/S 16/R 2/S ≥ 64/R
E. coli ATCC 25,922 LC-MS/MS results*** 100 100 100 100 100 100
MIC results** 8/S 0.25/S 0.06/S 0.12/S 0.12/S 0.5/S
K. pneumoniae (1) LC-MS/MS results* 0.9/R 55.6/R 39.9/R 38.4/R 71.9/R 62.5/R
MIC results** ≥32/R ≥ 16/R ≥ 16/R 8/R 16/R ≥ 64/R
K. pneumoniae (2) LC-MS/MS results* 0.5/R 0.1/R 0.3/R 0.3/R 92.1/S 0.5/R
MIC results** ≥ 32/R 8/R 4/R ≥ 64/R 8/SDD 16/R
P. stuartii**** LC-MS/MS results* N/A 0/R 0/R 9.9/R 22.4/R 19.1/R
MIC results** N/A ≥ 16/R ˃ 16/R ≥ 64/R 16/R ≥ 64/R
A. baumannii**** LC-MS/MS results* N/A 0/R 21.3/R 14.6/R 43.5/R 29.3/R
MIC results** N/A ≥ 16/R ≥ 16/R ≥ 64/R ≥ 64/R ≥ 64/R
E. coli (1) LC-MS/MS results* 42/R 93.2/S 103.1/S 21.1/R 63.3/R 87.6/S
MIC results** ≥ 32/R ≤ 0.25/S ≤ 0.25/S ≥ 64/R ≥ 64/R 8 I
E. coli (2) LC-MS/MS results* 22.6/R 92.5/S 90.2/S 27.8/R 52/R 34.5/R
MIC results** ˃128/R ≤ 0.25/S ≤ 0.25/S ≥ 64/R 16/R ≥ 64/R
E. coli (3) LC-MS/MS results* 12/R 95/S 91/S 25/R 54/R 37/R
MIC results** ≥128/R ≤ 0.25/S ≤ 0.25/S ≥ 64/R 16/R ≥ 32/R
Notes: *Results expressed as a percentage of unhydrolyzed antibiotic, hydrolysis is considered present where more than 10% of antibiotic is hydrolyzed for AMP, IMI, MEM 
and FEP; and 15% for CRO and CAZ. Concentrations of antibiotics: 5 mg/mL for AMP and 0.5 mg/mL for IMI, MEM, CRO, FEP, CAZ. **Results expressed as minimum 
inhibitory concentration of antibiotic (µg/mL) that can inhibit the growth of bacteria. Susceptibility or resistance were defined according to CLSI breakpoints. For all 
reference strains MIC corresponded to CLSI qualitative control ranges. ***Strain sensitive to all antibiotics and used as negative control, percentage of unhydrolyzed 
antibiotic is 100. ****Providencia and Acinetobacter are intrinsically resistant to ampicillin.20 Therefore, in these cases, values of hydrolysis and MC assays for ampicillin do not 
have clinical utility. 
Abbreviations: R, resistant; S, sensitive; I, intermediate; SSD, susceptible dose dependent; AMP, ampicillin; IMI, imipenem; MEM, meropenem; CRO, ceftriaxone; FEP, 
cefepime; CAZ, ceftazidime, N/A, not applicable.
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bacterial suspension (McFarland 1) and a shorter incuba-
tion (1h) were also evaluated in the current study (results 
not shown). We found that using less concentrated bacter-
ial suspension and shorter incubation as previously 
reported16–18 did not either produce detectable level of 
hydrolysis of any of the antibiotics or the result was not 
conclusive. The reason for this may be attributable to 
different experiment conditions, such as the number of 
antibiotics used. In the present study, a greater number of 
antibiotics were used for the hydrolysis test which required 
more enzyme and thus a more concentrated bacteria sus-
pension. Although a longer incubation time is required in 
the current study, it can be used to measure enzyme 
activity of an organism towards several antibiotics 
simultaneously.
The protocol developed in the current study could 
reduce antibiotic resistance testing turnaround time by 
several hours, time that could be decisive in disease out-
come. We estimated that the time required for completing 
the test, including sample preparation and incubation, is 
Figure 2 Hydrolysis level of each antibiotic for Klebsiella pneumoniae ATCC BAA-1705, Acinetobacter baumannii and Escherichia coli. 
Note: * Results expressed in percentage of unhydrolyzed antibiotic 
Abbreviations: AMP, ampicillin; IMI, imipenem; MEM, meropenem; CRO, ceftriaxone; FEP, cefepime; CAZ,ceftazidime.
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between 3 to 5 h, time that could be influenced by the 
number of samples and operator experience. In compari-
son, MIC test using the commercial antimicrobial suscept-
ibility platform can take up to 8 h to complete.26 Estimated 
advantages and disadvantages of the two methods are 
shown in Table 5.
The discrepancies with the MIC test for intermediate and 
SDD strains could be explained by the fact that the MIC is 
a dynamic test where the bacteria are maintained in a nutrient 
environment, where the enzyme is constantly being pro-
duced. In comparison, the sample of bacteria used in the 
hydrolysis test contains a fixed level of enzyme. The finding 
that one K. pneumoniae SDD to cefepime strain was diag-
nosed as sensitive using the LC-MS/MS test could represent 
a limitation especially because it is known that a high pro-
portion of K. pneumoniae strains fall into SDD category.27 
Therefore, we consider that further research should be done 
using several intermediate and SDD strains in combination 
with incubation in nutrient media to confirm if this is 
a limitation. This could provide more consistent results that 
meet the CLSI criteria-compliant MIC testing. The calcu-
lated specificity in the case of cefepime and ceftazidime may 
not reflect the performance of the assay very well since the 
intermediate and SSD strains give a different result. 
Therefore, future studies should include an appropriate sta-
tistical method to assess the assay performance. Also, the fact 
that we did not have reference strains for every isolated 
species could be a limitation.
Conclusions
The present study proposes a protocol for detecting β- 
lactamase activity in Gram-negative bacilli with improved 
robustness and multiplexing over previously described 
LC-MS/MS- and MALDI-based protocols. This has been 
achieved by using sensitive strains to validate the results in 
every experiment and using six antibiotics from three 
different classes. However, we estimate that for a broad 
assimilation of the method for routine testing, further 
research is needed, especially for strains with intermediate 
resistance.
Disclosure
The authors report no conflicts of interest in this work.
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